Veracyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Veracyte (NASDAQ: VCYT) has announced that CEO Marc Stapley and CFO Rebecca Chambers will present at two key investor conferences. The first is Cowen's 43rd Annual Health Care Conference in Boston on March 7, 2023, at 9:50 AM ET. The second event is the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21, 2023, at 3:45 PM ET. Live webcasts of these presentations can be accessed via Veracyte’s website, with replays available for 90 days post-event. Veracyte aims to transform cancer care globally with innovative diagnostic tests that help clinicians make better decisions and improve patient outcomes.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.

• Cowen’s 43rd Annual Health Care Conference – Boston, MA
  Presentation on March 7^th at 9:50 a.m. Eastern Time
  

• KeyBanc Virtual Life Sciences & MedTech Investor Forum
  Fireside Chat on March 21^st at 3:45 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005850/en/

Investors:

Shayla Gorman

Director, Investor Relations

investors@veracyte.com

619-393-1545

Media:

Tracy Morris

Vice President of Global Corporate Communications

tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

When will Veracyte present at the Cowen's 43rd Annual Health Care Conference?

Veracyte will present at Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 9:50 AM ET.

What is the date of Veracyte's participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum?

Veracyte will participate in the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21, 2023, at 3:45 PM ET.

Where can I listen to the live webcasts of Veracyte's investor presentations?

Live webcasts of Veracyte's investor presentations can be accessed on their website's events and presentations section.

What is Veracyte's mission in cancer diagnostics?

Veracyte's mission is to transform cancer care globally by providing innovative diagnostic tests that guide clinicians in making informed decisions.

What types of cancers does Veracyte focus on with its diagnostic tests?

Veracyte focuses on diagnostics for thyroid, prostate, breast, bladder, and lung cancers, as well as interstitial lung diseases.